DOJ cuts deferred prosecution deal with bankrupt pharma

The Department of Justice’s antitrust division has charged Rising Pharmaceuticals with conspiring to fix prices and allocate customers for a generic hypertension drug, but resolved the charge with a deferred prosecution agreement.


Get unlimited access to all Global Competition Review content